<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27519" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Postinflammatory Hyperpigmentation</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lawrence</surname>
            <given-names>Elizabeth</given-names>
          </name>
          <aff>University of South Florida, Morton Plant Mease</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Al Aboud</surname>
            <given-names>Khalid M.</given-names>
          </name>
          <aff>King Faisal Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Elizabeth Lawrence declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Khalid Al Aboud declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27519.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Postinflammatory hyperpigmentation (PIH) is a common acquired disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III&#x02013;VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. This activity reviews the evaluation and management of postinflammatory hyperpigmentation and highlights the role of the interprofessional team in educating and managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of postinflammatory hyperpigmentation.</p></list-item><list-item><p>Assess&#x000a0;the steps in the evaluation of postinflammatory hyperpigmentation.</p></list-item><list-item><p>Differentiate&#x000a0;the management options available for postinflammatory hyperpigmentation.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for improving care coordination and communication to advance the treatment of postinflammatory hyperpigmentation and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27519&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27519">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27519.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III-VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.<xref ref-type="bibr" rid="article-27519.r1">[1]</xref><xref ref-type="bibr" rid="article-27519.r2">[2]</xref><xref ref-type="bibr" rid="article-27519.r3">[3]</xref></p>
      </sec>
      <sec id="article-27519.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>While any inflammatory skin condition can result in hyperpigmentation, the most common causes of PIH in patients with darker skin color are acne vulgaris, atopic dermatitis, and impetigo. Other etiologies include<xref ref-type="bibr" rid="article-27519.r1">[1]</xref><xref ref-type="bibr" rid="article-27519.r4">[4]</xref>:</p>
        <p>
<bold>Infections</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Viral exanthems</p>
          </list-item>
          <list-item>
            <p>Fungal infections</p>
          </list-item>
          <list-item>
            <p>Impetigo</p>
          </list-item>
        </list>
        <p>
<bold>Allergic/Immunologic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Contact dermatitis</p>
          </list-item>
          <list-item>
            <p>Atopic dermatitis</p>
          </list-item>
          <list-item>
            <p>Scleroderma</p>
          </list-item>
          <list-item>
            <p>Sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Systemic lupus erythematosus</p>
          </list-item>
          <list-item>
            <p>Dermatomyositis</p>
          </list-item>
          <list-item>
            <p>Insect bite reaction</p>
          </list-item>
        </list>
        <p>
<bold>Papulosquamous Disorders</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Psoriasis</p>
          </list-item>
          <list-item>
            <p>Lichen planus</p>
          </list-item>
          <list-item>
            <p>Pityriasis rosea</p>
          </list-item>
          <list-item>
            <p>Lichen simplex chronicus</p>
          </list-item>
        </list>
        <p>
<bold>Cutaneous Injury</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Laser/light therapy</p>
          </list-item>
          <list-item>
            <p>Burns</p>
          </list-item>
          <list-item>
            <p>Cryotherapy</p>
          </list-item>
          <list-item>
            <p>Chemical peels</p>
          </list-item>
          <list-item>
            <p>Radiation therapy</p>
          </list-item>
        </list>
        <p>
<bold>Medication Hypersensitivity Reactions</bold>
</p>
        <p>
<bold>Miscellaneous</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acne vulgaris</p>
          </list-item>
          <list-item>
            <p>Mycosis fungoides</p>
          </list-item>
          <list-item>
            <p>Erythema dyschromicum perstans</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27519.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>PIH can occur at any age in all skin types but is more common in Fitzpatrick skin types III-VI. The darker the skin color, the more intense and persistent hypermelanosis tends to be. There is no gender difference. The incidence of PIH in darker-skinned patients with acne can be as high as 65%.<xref ref-type="bibr" rid="article-27519.r4">[4]</xref><xref ref-type="bibr" rid="article-27519.r5">[5]</xref></p>
      </sec>
      <sec id="article-27519.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Postinflammatory hyperpigmentation, or hypermelanosis, results from the overproduction of melanin or abnormal melanin deposition in the epidermis or dermis following inflammation. Inflammatory mediators trigger melanocyte hypertrophy and activity, which increases melanin production in the epidermis. In deeper processes extending to the dermis, basal keratinocytes are damaged and release large amounts of melanin. The melanin is phagocytosed and deposited, causing a blue-gray discoloration of the skin, which may be permanent. Hyperpigmentation limited to the epidermis has a higher likelihood of resolution than dermal hyperpigmentation.<xref ref-type="bibr" rid="article-27519.r1">[1]</xref><xref ref-type="bibr" rid="article-27519.r6">[6]</xref></p>
      </sec>
      <sec id="article-27519.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>If a biopsy is performed, epidermal PIH histopathology is significant for increased melanin in keratinocytes. The presence of melanin in dermal macrophages is noted in dermal melanosis. A biopsy may also be useful in determining the etiology of the underlying inflammation.<xref ref-type="bibr" rid="article-27519.r7">[7]</xref><xref ref-type="bibr" rid="article-27519.r8">[8]</xref></p>
      </sec>
      <sec id="article-27519.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with PIH have a history of an inflammatory disorder of the skin or skin injury in the same distribution. Once the underlying inflammation has resolved, PIH is asymptomatic. However, psychological distress and impact on the quality of life may persist.</p>
        <p>On physical examination, PIH appears as irregular, hyperpigmented macules or patches in the initial inflammation or injury distribution. Epidermal hyperpigmentation is tan, brown, or dark brown and may persist for months to years without treatment but does tend to improve over time as the underlying inflammatory disorder resolves. Wood&#x02019;s lamp examination of epidermal PIH may reveal fluorescence. Dermal hyperpigmentation is blue-gray and may be permanent. Dermal and epidermal hyperpigmentation may both be present. If the inflammatory process is still active, erythematous papules, plaques, or nodules may also be visible.<xref ref-type="bibr" rid="article-27519.r1">[1]</xref><xref ref-type="bibr" rid="article-27519.r7">[7]</xref></p>
      </sec>
      <sec id="article-27519.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of PIH is clinical. Wood&#x02019;s lamp evaluation can help distinguish between epidermal and dermal PIH. A biopsy may be useful for confirming the diagnosis if the diagnosis is uncertain or if the underlying etiology has yet to be determined. Laboratory evaluation to rule out Addison's disease and systemic lupus erythematosus may be necessary if signs and symptoms are present.<xref ref-type="bibr" rid="article-27519.r4">[4]</xref></p>
      </sec>
      <sec id="article-27519.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of PIH is typically stepwise and includes multiple modalities in addition to daily protection against ultraviolet radiation. The first step is treating the causative inflammatory disorder if it is still active. Topical lightening therapy, often in combination, is next, followed by chemical peels and/or laser therapy for severe or refractory cases. Treatment, lasting months to years, is often required; patient education should set the expectation that improvement of hypomelanosis is slow and recurrences are common.</p>
        <p>
<bold>Topical Therapy</bold>
</p>
        <p><bold>Tyrosinase inhibitors:</bold>&#x000a0;prevent melanin production.</p>
        <p>The mainstay of treatment is a topical lightening agent such as hydroquinone. Mequinol can be used if a less irritating agent is needed. It is often combined with a topical retinoid with or without a topical steroid to enhance and speed effectiveness. A commonly used triple combination includes hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%. The topical steroid can lessen the irritant effects of the skin lightener and/or the retinoid. Still, it should only be used for up to 8 weeks to minimize the likelihood of steroid-induced skin changes. Topical retinoids include tretinoin, adapalene, and tazarotene. They effectively treat underlying acne and PIH and may be used long-term. Azelaic acid can also treat both acne and PIH.</p>
        <p>
<bold>Chemical Peels</bold>
</p>
        <p>Chemical peels work by removing the epidermal cells containing excess melanin. They must be used with caution by experienced clinicians as they can cause skin irritation and additional hyperpigmentation. Glycolic, salicylic, and trichloroacetic acid peels are common.&#x000a0;</p>
        <p>
<bold>Laser Therapy</bold>
</p>
        <p>Multiple laser types, including Q-switched ruby lasers, Q-switched Nd:YAG lasers, and picosecond (short, intense pulse) lasers have been used to treat PIH as has fractional photothermolysis. However, experienced clinicians should also use them cautiously, as they can cause skin irritation and additional hyperpigmentation.<xref ref-type="bibr" rid="article-27519.r4">[4]</xref><xref ref-type="bibr" rid="article-27519.r9">[9]</xref></p>
      </sec>
      <sec id="article-27519.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of postinflammatory hyperpigmentation includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Melasma</p>
          </list-item>
          <list-item>
            <p>Solar lentigines</p>
          </list-item>
          <list-item>
            <p>Tinea versicolor</p>
          </list-item>
          <list-item>
            <p>Acanthosis nigricans</p>
          </list-item>
          <list-item>
            <p>Lichen planus pigmentosus</p>
          </list-item>
          <list-item>
            <p>Macular amyloidosis</p>
          </list-item>
          <list-item>
            <p>Ochronosis (patchy hyperpigmentation)</p>
          </list-item>
          <list-item>
            <p>Erythema dyschromicum perstans morphea</p>
          </list-item>
          <list-item>
            <p>Discoid lupus erythematosis<xref ref-type="bibr" rid="article-27519.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27519.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Epidermal hyperpigmentation typically resolves or significantly improves within 6 to 12 months, whereas dermal hyperpigmentation improves slowly and may be permanent. No morbidity beyond psychological distress is associated with it, although recurrences are common, especially if photoprotection is not employed.<xref ref-type="bibr" rid="article-27519.r6">[6]</xref></p>
      </sec>
      <sec id="article-27519.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of untreated PIH include worsening hyperpigmentation and psychological distress. Complications of treatment include skin irritation and post-procedure hyperpigmentation.<xref ref-type="bibr" rid="article-27519.r6">[6]</xref><xref ref-type="bibr" rid="article-27519.r10">[10]</xref></p>
      </sec>
      <sec id="article-27519.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Dermatologic consultation may be helpful in refractory cases or if chemical peels or laser therapy are therapeutic considerations.</p>
      </sec>
      <sec id="article-27519.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Broad-spectrum, year-round ultraviolet radiation protection with sunscreen and protective clothing should be initiated at diagnosis and throughout treatment regardless of skin color. Patients with darker skin types may be less likely to use sun protection without education due to a lack of perceived importance.<xref ref-type="bibr" rid="article-27519.r7">[7]</xref></p>
      </sec>
      <sec id="article-27519.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Combination therapy is more effective than monotherapy. Aggressive treatment likely leads to skin irritation and further hyperpigmentation; patience is necessary. Patients should use broad-spectrum photoprotection daily.</p>
      </sec>
      <sec id="article-27519.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>All healthcare team members should work together to prevent and treat PIH by educating patients on using broad-spectrum sunscreen and protective clothing when sun avoidance is impossible. Education on the usually self-limiting nature of PIH is also helpful. Primary care providers may initiate treatment with topical agents and may choose to refer to dermatology for chemical peels or laser therapy.<xref ref-type="bibr" rid="article-27519.r4">[4]</xref><xref ref-type="bibr" rid="article-27519.r6">[6]</xref></p>
      </sec>
      <sec id="article-27519.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27519&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27519">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/postinflammatory-hyperpigmentation/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27519">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27519/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27519">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27519.s18">
        <title>References</title>
        <ref id="article-27519.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Callender</surname>
                <given-names>VD</given-names>
              </name>
            </person-group>
            <article-title>Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>3</volume>
            <issue>7</issue>
            <fpage>20</fpage>
            <page-range>20-31</page-range>
            <pub-id pub-id-type="pmid">20725554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27519.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaowattanapanit</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Silpa-Archa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kohli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Hamzavi</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Postinflammatory hyperpigmentation: A comprehensive overview: Treatment options and prevention.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>77</volume>
            <issue>4</issue>
            <fpage>607</fpage>
            <page-range>607-621</page-range>
            <pub-id pub-id-type="pmid">28917452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27519.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zubair</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Vellaichamy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hamzavi</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>What's New in Pigmentary Disorders.</article-title>
            <source>Dermatol Clin</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>175</fpage>
            <page-range>175-181</page-range>
            <pub-id pub-id-type="pmid">30850040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27519.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grimes</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Im</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lui</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Postinflammatory hyperpigmentation.</article-title>
            <source>J Cutan Med Surg</source>
            <year>2009</year>
            <season>Jul-Aug</season>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>183</fpage>
            <page-range>183-91</page-range>
            <pub-id pub-id-type="pmid">19706225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27519.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huerth</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Callender</surname>
                <given-names>VD</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic Insights in Melasma and Hyperpigmentation Management.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2019</year>
            <month>Aug</month>
            <day>01</day>
            <volume>18</volume>
            <issue>8</issue>
            <fpage>718</fpage>
            <page-range>718-729</page-range>
            <pub-id pub-id-type="pmid">31424704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27519.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plensdorf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Livieratos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dada</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Pigmentation Disorders: Diagnosis and Management.</article-title>
            <source>Am Fam Physician</source>
            <year>2017</year>
            <month>Dec</month>
            <day>15</day>
            <volume>96</volume>
            <issue>12</issue>
            <fpage>797</fpage>
            <page-range>797-804</page-range>
            <pub-id pub-id-type="pmid">29431372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27519.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Treatment of hyperpigmentation.</article-title>
            <source>Facial Plast Surg Clin North Am</source>
            <year>2011</year>
            <month>May</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>313</fpage>
            <page-range>313-24</page-range>
            <pub-id pub-id-type="pmid">21763992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27519.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isedeh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kohli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Al-Jamal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Agbai</surname>
                <given-names>ON</given-names>
              </name>
              <name>
                <surname>Chaffins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Devpura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mahan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vanderover</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Matsui</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hamzavi</surname>
                <given-names>IH</given-names>
              </name>
            </person-group>
            <article-title>An in vivo model for postinflammatory hyperpigmentation: an analysis of histological, spectroscopic, colorimetric and clinical traits.</article-title>
            <source>Br J Dermatol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>174</volume>
            <issue>4</issue>
            <fpage>862</fpage>
            <page-range>862-8</page-range>
            <pub-id pub-id-type="pmid">26663029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27519.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Passeron</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Genedy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Salah</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fusade</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kositratna</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Laubach</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Marini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Badawi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Laser treatment of hyperpigmented lesions: position statement of the European Society of Laser in Dermatology.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>987</fpage>
            <page-range>987-1005</page-range>
            <pub-id pub-id-type="pmid">30873649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27519.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darji</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Varade</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Armbrecht</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Psychosocial Impact of Postinflammatory Hyperpigmentation in Patients with Acne Vulgaris.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2017</year>
            <month>May</month>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>18</fpage>
            <page-range>18-23</page-range>
            <pub-id pub-id-type="pmid">28670354</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
